Tenofovir in the treatment of hepatitis B virus infection after liver transplantation, a single center large population study
Gastroenterology and Hepatology from Bed to Bench,
Vol. 14 No. 2 (2021),
8 March 2021
,
Page 154-159
https://doi.org/10.22037/ghfbb.v14i2.1961
Abstract
Aim: This study investigated the safety and efficacy of tenofovir disoproxil fumarate (TDF) compared with lamivudine (LAM) in the prevention of recurrent HBV infection after liver transplantation (LT).
Background: Although the recurrence of hepatitis B virus after liver transplantation (LT) is now very uncommon with both nucleoside and nucleotide analogs represented with lamivudine and tenofovir disoproxil fumarate, respectively, few studies have compared the two classes.
Methods: A total of 302 HBV-related post-transplant patients who received liver transplants from deceased donors were enrolled in this retrospective study from 2011 to 2015 in the Shiraz Organ Transplant Center, Iran. The demographic data, kidney function, recurrence, resistance rate, and acute rejections at 1-, 6-, and 12-month intervals and after 12 months were compared on TDF (n=209) and lamivudine (n=93) groups.
Results: During a median follow-up period of 42.9 months, mean creatinine level was not significantly different between the two groups. Hepatitis B virus recurrence rate as well as acute graft rejection episode had no statistical difference in either group over the study period.
Conclusion: Kidney function, creatinine level, disease recurrence, and acute graft rejection were comparable between tenofovir disoproxil fumarate and lamivudine in patients who received follow-up periods.
Keywords: Hepatitis B, Liver transplantation, Therapeutics.
(Please cite as: Ejtehadi F, Pashaei MR, Shamsaeefar AR, Motazedian N, Sivandzadeh GR, Niknam R, et al. Tenofovir in the treatment of hepatitis B virus infection after liver transplantation, a single center large population study. Gastroenterol Hepatol Bed Bench 2021;14(2):154-159).
- Hepatitis B
- liver transplantation
- Therapeutics
How to Cite
References
Veerappan A, VanWagner LB, Mathew JM, Huang X, Miller J, Lapin B, et al. Low incidence of acute rejection in hepatitis B virus positive liver transplant recipients and the impact of hepatitis B immunoglobulin. Hum. Immunol 2016; 77:367-74.
Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article.
J Res Med Sci 2009; 14:249-58. Epub 2009/07/01.
Xi Z-F, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015;21:829-35.
Perrakis A, Fortsch T, Del Medico A, Croner RS, Vassos N, Yedibela S, et al. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection. Transplant Proc 2013; 45:1953-6.
Stravitz RT, Shiffman ML, Kimmel M, Puri P, Luketic VA, Sterling RK, et al. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012; 32:1138-45.
Hakim GD, Akarsu M, Karademir S, Unek T, Astarcioglu I. The efficacy and safety of tenofovir in the prevention of hepatitis B virus recurrence following liver transplantation. Turk J Gastroenterol 2014; 25:685-9.
Tanaka T, Renner EL, Selzner N, Therapondos G, Lilly LB. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. Can J Gastroenterol Hepatol 2014; 28:41-4.
Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int 2014; 27:1022-8.
Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol 2014 Dec 1; 12:2106-12.
Shin JH, Kwon HJ, Jang HR, Lee JE, Gwak GY, Huh W, et al. Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents. Medicine 2016 Jan;95.
van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection. Hepatology 2004; 40:1421-5.
Fernandez I, Loinaz C, Hernandez O, Abradelo M, Manrique A, Calvo J, et al. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transplant Infect Dis 2015; 17:695-701.
Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013; 19:594-601.
Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13:353-62.
Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29:1294-305.
Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant 2012;26: E561-9.
Cho WH, Lee HJ, Bang KB, Kim SB, Song IH. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: a case report and review of the literature. World J Gastroenterol 2018; 24:1919-24.
Yoshida H, Kato T, Levi DM, Regev A, Madariaga JR, Nishida S, et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21:166-71.
Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, et al. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol 2018;10:352-70.
- Abstract Viewed: 41 times
- PDF Downloaded: 34 times